INTERLEUKIN-4 RECEPTORS ON NORMAL HUMAN B-LYMPHOCYTES - CHARACTERIZATION AND REGULATION

被引:41
作者
ZUBER, CE [1 ]
GALIZZI, JP [1 ]
VALLE, A [1 ]
HARADA, N [1 ]
HOWARD, M [1 ]
BANCHEREAU, J [1 ]
机构
[1] DNAX RES INST MOLEC & CELLULAR BIOL INC,RES INST,PALO ALTO,CA
关键词
D O I
10.1002/eji.1830200314
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human interleukin 4 (IL 4) up‐regulates the expression of CD23 on both resting and “in vivo” activated B cells but induces proliferation and/or differentiation only on “in vitro” activated B lymphocytes. Resting B cells express 360 high‐affinity IL 4 receptors (R) per cell (Kd = 25–75 pM). Activation of resting B cells with anti‐IgM antibody or Staphylococcus aureus Cowan I (SAC) results in a two‐to‐threefold increase of IL 4R number without alteration of IL 4R affinity for IL 4. Flow cytometric analysis of biotinylated IL 4 binding shows that IL 4R expression is up‐regulated on virtually all anti‐IgM‐stimulated B cells, but only on a subpopulation of larger cells among SAC‐activated B lymphocytes. Culturing cells for 40 h with optimal concentrations of IL 4 does not significantly affect IL 4R levels on resting and anti‐IgM‐preactivated B lymphocytes but triples IL 4R levels on SAC‐preactivated B cells. Removal of IL 4 from cell cultures results in a two‐to‐fourfold increase of IL 4R levels 2 h later, suggesting an increase in IL 4R turnover. Resting and activated B cells degrade 1251‐labeled IL 4 at 37 °C. Sodium dodecyl sulfate‐polyacrylamide gel electrophoretic analysis of IL 4 binding molecules on resting, “in vivo” activated and anti‐IgM‐activated B cells reveals the same three species of 130, 80‐75, 70‐65 kDa. Thus, IL 4 displays its different biological activities on resting and activated B cells through IL 4R of the same affinity, gross biochemical structure and ability to mediate IL 4 degradation. Copyright © 1990 Wiley‐VCH Verlag GmbH & Co. KGaA, Weinheim
引用
收藏
页码:551 / 555
页数:5
相关论文
共 21 条
[1]   HIGH-AFFINITY BINDING OF HUMAN INTERLEUKIN-4 TO CELL-LINES [J].
CABRILLAT, H ;
GALIZZI, JP ;
DJOSSOU, O ;
ARAI, N ;
YOKOTA, T ;
ARAI, K ;
BANCHEREAU, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 149 (03) :995-1001
[2]  
CAMBIER JC, 1987, IMMUNOL REV, V95, P36
[3]   HUMAN INTERLEUKIN-4 DOWN-REGULATES THE SURFACE EXPRESSION OF CD5 ON NORMAL AND LEUKEMIC B-CELLS [J].
DEFRANCE, T ;
VANBERVLIET, B ;
DURAND, I ;
BANCHEREAU, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1989, 19 (02) :293-299
[4]  
DEFRANCE T, 1988, J IMMUNOL, V141, P2000
[5]   HUMAN RECOMBINANT INTERLEUKIN-4 INDUCES FC-EPSILON RECEPTORS (CD23) ON NORMAL HUMAN LYMPHOCYTES-B [J].
DEFRANCE, T ;
AUBRY, JP ;
ROUSSET, F ;
VANBERVLIET, B ;
BONNEFOY, JY ;
ARAI, N ;
TAKEBE, Y ;
YOKOTA, T ;
LEE, F ;
ARAI, K ;
DEVRIES, J ;
BANCHEREAU, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 165 (06) :1459-1467
[6]  
DEFRANCE T, 1987, J IMMUNOL, V139, P1135
[7]   INTERLEUKIN-4 ACTIVATES HUMAN LYMPHOCYTES-B VIA TRANSIENT INOSITOL LIPID HYDROLYSIS AND DELAYED CYCLIC ADENOSINE-MONOPHOSPHATE GENERATION [J].
FINNEY, M ;
GUY, GR ;
MICHELL, RH ;
GORDON, J ;
DUGAS, B ;
RIGLEY, KP ;
CALLARD, RE .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1990, 20 (01) :151-156
[8]  
GALIZZI JP, 1989, J BIOL CHEM, V264, P6984
[9]  
GALIZZI JP, 1988, J IMMUNOL, V141, P1982
[10]  
LE HV, 1988, J BIOL CHEM, V263, P10817